PointState Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

PointState Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-20,000	Closed	-$2.91M	–	110
2015 Q3	$2.91M	Sell	20,000 -2,500	-11%	-$459K	0.08%	74
2015 Q2	$4.79M	Buy	22,500 +2,500	+13%	+$613K	0.06%	107
2015 Q1	$4.63M	Sell	20,000 -5,000	-20%	-$1.21M	0.06%	96
2014 Q4	$5.76M	Buy	+25,000	New	+$5.36M	0.1%	90

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

PointState Capital's BLCM Position: Q4 2015 in Review

PointState Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2015, closing a stake of 20,000 shares — an estimated $2.91M sold.

PointState Capital first reported a position in BLCM in Q4 2014 and held it in 4 quarters. The position peaked at $5.76M in Q4 2014. 81 funds tracked by Wall St. Rank hold BLCM as of Q4 2015.

PointState Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
PointState Capital sold 20,000 Bellicum Pharmaceuticals, Inc. shares in Q4 2015, an estimated $2.91M.
PointState Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
PointState Capital's Bellicum Pharmaceuticals, Inc. position peaked at $5.76M in Q4 2014.
81 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2015.

Based on PointState Capital's 13F filing for Q4 2015, filed 16 Feb 2016.